[미국특허]
Antibodies for oncogenic strains of HPV and methods of their use
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/08
G01N-033/569
G01N-033/574
출원번호
US-0310138
(2014-06-20)
등록번호
US-9611315
(2017-04-04)
발명자
/ 주소
Lu, Peter S.
Garman, Jonathan David
Belmares, Michael P.
Diaz-Sarmiento, Chamorro Somoza
Schweizer, Johannes
출원인 / 주소
Arbor Vita Corporation
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
37
초록▼
The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HP
The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.
대표청구항▼
1. A monoclonal antibody that is non-human and that binds to a sub-sequence of a common sequence of an early gene protein from at least two oncogenic human papillomavirus (HPV) strains selected from the group consisting of HPV strains 16, 18, 31, 33, 52, and 58, wherein the common sequence is an ami
1. A monoclonal antibody that is non-human and that binds to a sub-sequence of a common sequence of an early gene protein from at least two oncogenic human papillomavirus (HPV) strains selected from the group consisting of HPV strains 16, 18, 31, 33, 52, and 58, wherein the common sequence is an amino acid sequence motif that is conserved within a same gene protein from the at least two oncogenic HPV strains, wherein the common sequence comprises at least 9 contiguous amino acids within a region of sequence similarity between the same early gene protein of the at least two oncogenic HPV strains, wherein the region of sequence similarity is located within amino acids 1-43 of the N-terminus of the same early gene protein or within 41 amino acids of the C-terminus of the same early gene protein, and wherein: a) the early gene protein from the at least two oncogenic HPV strains is encoded by a nucleic acid sequence within the HPV early gene protein 6-HPV early gene protein 7 (E6-E7) region of an HPV genome; andb) a dissociation constant of the monoclonal antibody for the early gene protein from the at least two oncogenic HPV strains is less than 10−5 M. 2. The monoclonal antibody of claim 1, wherein the antibody binds to SEQ ID NO: 7 or 8 with a dissociation constant of less than 10−5 M. 3. The monoclonal antibody of claim 1, wherein the antibody binds to an E6 peptide having SEQ ID NO: 11 or 12 with a dissociation constant of less than 10−5 M. 4. The monoclonal antibody of claim 1, wherein the antibody binds to an HPV E6 peptide having SEQ ID NO: 1, 2, 3, 4, 5, 6, 57, 58, or 59 with a dissociation constant of less than 10−5 M. 5. The monoclonal antibody of claim 1, wherein the antibody has a dissociation constant of less than 10−7 M for each of the at least two oncogenic strains. 6. The monoclonal antibody of claim 1, wherein the antibody has a dissociation constant of less than 10−8 M for each of the at least two oncogenic strains. 7. The monoclonal antibody of claim 1, wherein the antibody has a dissociation constant of less than 10−9 M for each of the at least two oncogenic strains. 8. An antibody composition comprising a mixture of monoclonal antibodies that bind to HPV early protein 6 (E6) proteins of oncogenic human papillomavirus (HPV) strains, wherein at least one of said monoclonal antibodies is the monoclonal antibody according to claim 1. 9. The antibody composition of claim 8, wherein at least said monoclonal antibody according to claim 1 binds to an E6 peptide having SEQ ID NO: 1, 2, 3, 4, 5, 6, 57, 58, or 59. 10. The antibody composition of claim 8, wherein said mixture of monoclonal antibodies binds to E6 proteins of HPV strains 16, 18, and 45. 11. The antibody composition of claim 8, wherein said mixture of monoclonal antibodies binds to E6 proteins of HPV strains 16, 18, 31, 33, 45, 52, 58, 35 and 59. 12. A diagnostic kit for the detection of a human papillomavirus (HPV) E6 polypeptide in a sample, comprising: the antibody composition of claim 8. 13. The diagnostic kit of claim 12, wherein said monoclonal antibodies are labeled. 14. The diagnostic kit of claim 12, further comprising a PDZ domain polypeptide that binds to an oncogenic HPV E6 polypeptide in a sample. 15. A method of detecting a human papillomavirus (HPV) E6 protein in a sample, comprising: contacting the antibody composition of claim 8 with said sample; and detecting any binding of said antibodies within said composition to said sample, wherein binding of said antibodies within said composition to said sample indicates the presence of an HPV E6 protein. 16. The method of claim 15, wherein said sample is suspected of containing an oncogenic strain of HPV. 17. A method of detecting the presence of an oncogenic human papillomavirus (HPV) early protein 6 (E6) protein in a sample, said method comprising: contacting a sample with a PDZ domain polypeptide; and detecting any binding of said oncogenic HPV E6 protein to said sample to said PDZ domain polypeptide using the antibody composition of claim 8; wherein binding of said oncogenic HPV E6 protein to said PDZ domain polypeptide indicates the presence of an oncogenic HPV E6 protein in said sample. 18. A system for detecting the presence of an oncogenic human papillomavirus (HPV) early protein 6 (E6) polypeptide in a sample, said system comprising: a first and a second binding partner for an oncogenic HPV E6 polypeptide, wherein said first binding partner is a PDZ domain protein and said second binding partner is the antibody of claim 1. 19. The system of claim 18, wherein at least one of said binding partners is attached to a solid support. 20. The monoclonal antibody of claim 1, wherein the at least two oncogenic HPV strains are selected from the group consisting of HPV strains: 16, 31, and 33. 21. The monoclonal antibody of claim 1, wherein the at least two oncogenic HPV strains are selected from the group consisting of HPV strains: 52, and 58. 22. The monoclonal antibody of claim 1, wherein the at least two oncogenic HPV strains are selected from the group consisting of HPV strains: 16 and 18. 23. The monoclonal antibody of claim 1, wherein the early gene protein is E6. 24. The monoclonal antibody of claim 1, wherein the antibody binds the oncogenic protein encoded by a nucleic acid sequence that encodes for a protein selected from the group consisting of SEQ ID NOs: 13, 14, 15, 16, 17, and 18 with a dissociation constant of less than 10−5 M. 25. The monoclonal antibody of claim 1, wherein the common sequence has a sequence corresponding to SEQ ID NO: 1. 26. The monoclonal antibody of claim 1, wherein the sub-sequence has a sequence corresponding to SEQ ID NO: 7. 27. The monoclonal antibody of claim 1, wherein the monoclonal antibody is a humanized antibody. 28. The monoclonal antibody of claim 1, wherein the monoclonal antibody is a chimeric antibody. 29. The monoclonal antibody of claim 1, wherein the dissociation constant of the monoclonal antibody for the early gene protein from the at least two oncogenic HPV strains is less than 10−5 M when measured by direct enzyme-linked immunosorbent assay (ELISA). 30. The monoclonal antibody of claim 1, wherein the dissociation constant of the monoclonal antibody for the early gene protein from the at least two oncogenic HPV strains is less than 10−8 M when measured by direct enzyme-linked immunosorbent assay (ELISA). 31. The monoclonal antibody of claim 1, wherein the monoclonal antibody is a mouse antibody.
Lu,Peter S.; Garman,Jonathan David; Belmares,Michael P.; Somoza Diaz Sarmiento,Chamorro; Schweizer,Johannes, Antibodies for oncogenic strains of HPV and methods of their use.
Dillner Joakim (Stockholm CA SEX) Lerner Richard A. (La Jolla CA) Smith Richard (Del Mar CA) Parks D. Elliot (Del Mar CA), Antibodies to human papillomavirus latent proteins, diagnostic systems and methods.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Apparatus for transporting substances into living cells and tissues.
Stewart Cole FR; Rolf E. Streeck FR, Determined DNA sequenced derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions.
Cole Stewart (Chatillon Sous Bagneux FRX) Streeck Rolf E. (La Celle St-Cloud FRX), Determined DNA sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the produ.
Komly Carol Ann,FRX ; Croissant Odile,FRX ; Breitburd Francoise,FRX, Polypeptides and antibodies characteristics of papillomavirus, and diagnostic procedures and vaccines making use of the.
Orth Gerard (Sceaux FRX) Volpers Christoph (Wiesbaden DEX) Streeck Rolf E. (Wiesbaden DEX), Polypeptides encoded by DNA sequences derived from the genome of the papillomavirus HPV39, antibodies thereto, and their.
Muller Martin (Heidelberg DEX) Gissmann Lutz (Wiesloch DEX), Use of HVP-16 E6 and E7-gene derived peptides to diagnose HPV-16-associated invasive cervical cancer.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.